{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:44Z","timestamp":1787009444720,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Oxford Immunotec USA, Inc"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic hematopoietic cell transplant (alloHCT). We explored whether a change in CMV cell-mediated immunity during the first month after transplant predicts the risk of development of CMV infection and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This follow-up analysis is based on data from the REACT study, a multicenter prospective observational study of recipients of alloHCT who were CMV-seropositive. Production of interferon \u03b3 following ex vivo stimulation with CMV antigens IE1 (immediate early 1) and pp65 (phosphoprotein 65) was assessed by CMV ELISPOT assay at baseline and 2 and 4 weeks after transplant. Clinically significant CMV infection (CS-CMVi) was defined as CMV viremia and\/or disease necessitating antiviral therapy. We evaluated the impact of CMV CMI changes on the risk of CS-CMVi and post transplant mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 226 recipients of alloHCT with CMV cell-mediated immunity data at baseline and 2 and\/or 4 weeks after transplant. CS-CMVi occurred in 64 patients (28%). On Cox regression analyses, independent predictors of CS-CMVi included a negative \u0394 change from baseline to week 2 of pp65 spot counts (hazard ratio, 3.65 [95% CI, 1.65\u20138.04]; P = .001) to week 4 of IE1 spot counts (hazard ratio, 2.79 [95% CI, 1.46\u20135.35]; P = .002), anti-thymocyte globulin conditioning regimen, type of transplant, female sex, and corticosteroid use. Kaplan-Meir analysis showed a significant association of a negative IE1 change from baseline to week 4 and increased all-cause mortality after transplant (log rank test = 0.041).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A decrease in CMV-specific T-cell responses during the first month after transplant may predict CS-CMVi and is associated with all-cause mortality in recipients of alloHCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofad386","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T20:35:29Z","timestamp":1689798929000},"source":"Crossref","is-referenced-by-count":15,"title":["Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-6177","authenticated-orcid":false,"given":"Ella J","family":"Ariza-Heredia","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew J","family":"Winston","sequence":"additional","affiliation":[{"name":"Ronald Reagan UCLA Medical Center , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Rowley","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center , Hackensack, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Mullane","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranatharthi","family":"Chandrasekar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Karmanos Cancer Center, Wayne State University , Detroit, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin , Milwaukee, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-3619","authenticated-orcid":false,"given":"Robin K","family":"Avery","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases (Transplant Oncology), Johns Hopkins University , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl S","family":"Peggs","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute and University College London Hospitals National Health Service Foundation Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[{"name":"Transplant Infectious Diseases, University Health Network , Toronto , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneesh","family":"Nath","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant, Banner MD Anderson Cancer Center , Gilbert, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[{"name":"Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Huddinge, and Department of Medicine Huddinge, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif B","family":"Mossad","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Respiratory Institute, Cleveland Clinic , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"El Haddad","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida , Gainesville, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimpy P","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Mays Cancer Center at UT Health San Antonio MD Anderson , San Antonio, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareed","family":"Khawaja","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeet","family":"Dadwal","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, City of Hope , Duarte, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Oxford Immunotec USA , Marlborough, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"key":"2023082618334883600_ofad386-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia","year":"2014","journal-title":"Cancer Lett"},{"key":"2023082618334883600_ofad386-B2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/tri.12318","article-title":"Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm","volume":"27","author":"L\u00facia","year":"2014","journal-title":"Transpl Int"},{"key":"2023082618334883600_ofad386-B3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/bmt.2008.403","article-title":"Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT","volume":"43","author":"Pourgheysari","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2023082618334883600_ofad386-B4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/erm.10.109","article-title":"QuantiFERON-CMV assay for the assessment of cytomegalovirus cell-mediated immunity","volume":"11","author":"Giulieri","year":"2011","journal-title":"Expert Rev Mol Diagn"},{"key":"2023082618334883600_ofad386-B5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4110\/in.2017.17.5.317","article-title":"Comparison of the commercial QuantiFERON-CMV and overlapping peptide-based ELISPOT assays for predicting CMV infection in kidney transplant recipients","volume":"17","author":"Kwon","year":"2017","journal-title":"Immune Netw"},{"key":"2023082618334883600_ofad386-B6","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1128\/JVI.79.9.5400-5413.2005","article-title":"Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting","volume":"79","author":"Pahl-Seibert","year":"2005","journal-title":"J Virol"},{"key":"2023082618334883600_ofad386-B7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.transproceed.2009.12.030","article-title":"Monitoring cytomegalovirus T-cell immunity in small bowel\/multivisceral transplant recipients","volume":"42","author":"Chiereghin","year":"2010","journal-title":"Transplant Proc"},{"key":"2023082618334883600_ofad386-B8","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/infdis\/jiy592","article-title":"The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients","volume":"219","author":"El Haddad","year":"2018","journal-title":"J Infect Dis"},{"key":"2023082618334883600_ofad386-B9","first-page":"2365","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023082618334883600_ofad386-B10","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/infdis\/jiw064","article-title":"Utility of the enzyme-linked immunospot interferon-\u03b3-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients","volume":"213","author":"Nesher","year":"2016","journal-title":"J Infect Dis"},{"key":"2023082618334883600_ofad386-B11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Disease definitions working group of the cytomegalovirus drug development, definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023082618334883600_ofad386-B12","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2023082618334883600_ofad386-B13","article-title":"Immune monitoring with the T-SPOT CMV assay of allogeneic hematopoietic cell transplant (allo-HCT) recipients: a proof of concept in the clinical setting","author":"Nesher","year":"2014"},{"key":"2023082618334883600_ofad386-B14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cyto.b.20420","article-title":"Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations","volume":"74","author":"Gratama","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"2023082618334883600_ofad386-B15","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2002-08-2502","article-title":"Primary immune responses to human CMV: a critical role for IFN-\u03b3-producing CD4+ T cells in protection against CMV disease","volume":"101","author":"Gamadia","year":"2003","journal-title":"Blood"},{"key":"2023082618334883600_ofad386-B16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jcv.2016.11.012","article-title":"Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients","volume":"87","author":"Jung","year":"2017","journal-title":"J Clin Virol"},{"key":"2023082618334883600_ofad386-B17","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2009-12-234096","article-title":"Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update","volume":"115","author":"Seggewiss","year":"2010","journal-title":"Blood"},{"key":"2023082618334883600_ofad386-B18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3324\/haematol.2012.072991","article-title":"Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant","volume":"98","author":"McIver","year":"2013","journal-title":"Haematologica"},{"key":"2023082618334883600_ofad386-B19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/17512433.2018.1500897","article-title":"Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients","volume":"11","author":"Foolad","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2023082618334883600_ofad386-B20","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V83.7.1971.1971","article-title":"Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis","volume":"83","author":"Li","year":"1994","journal-title":"Blood"},{"key":"2023082618334883600_ofad386-B21","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad386\/50930700\/ofad386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/8\/ofad386\/51273688\/ofad386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/8\/ofad386\/51273688\/ofad386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T14:34:08Z","timestamp":1693060448000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad386\/7227942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad386","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,7,22]]},"article-number":"ofad386"}}